文献速递儿童神经与发育行为儿童消化与营养儿童血液肿瘤与免疫

医用大麻素在儿童和青少年中的安全性的系统综述与荟萃分析

Cannabinoids Used for Medical Purposes in Children and Adolescents: A Systematic Review and Meta-Analysis.
PubMed 文献 · JAMA Pediatr · 2024-01-01

该系统综述与荟萃分析纳入23项随机临床试验共3612名参与者,评估儿童和青少年医用大麻素的不良事件概况。与对照组相比,大麻素与总体不良事件风险增加、因不良事件退出风险增加及严重不良事件风险增加相关。常见不良事件包括腹泻、转氨酶升高和嗜睡。

要点

  • 医用大麻素在儿童和青少年中与总体不良事件风险增加相关(RR 1.09)。
  • 因不良事件退出风险(RR 3.07)和严重不良事件风险(RR 1.81)均增加。
  • 需关注腹泻、转氨酶升高和嗜睡等特定不良事件。

核心结论

  • 在随机临床试验中,儿童和青少年医用大麻素与不良事件风险增加相关。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE、Embase、PsycINFO和Cochrane Library从建库至2024年3月1日的随机临床试验。
  • 纳入23项RCT共3612名参与者,其中635名(17.6%)女性,2071名(57.3%)男性,2项试验数据不可用。
  • 11项试验(47.8%)仅纳入儿童和青少年,12项试验(52.2%)纳入儿童、青少年和成人。
  • 干预措施包括纯化大麻二酚(11项,47.8%)、纳比隆(4项,17.4%)、四氢大麻酚(3项,13.0%)、大麻草药提取物(3项,13.0%)和地沙那比诺(2项,8.7%)。
  • 最常见适应症为癫痫(9项,39.1%)和化疗引起的恶心呕吐(7项,30.4%)。

主要发现

  • 与对照组相比,大麻素与总体不良事件风险增加相关(RR 1.09;95% CI 1.02-1.16;I2=54%;12项试验)。
  • 大麻素与因不良事件退出风险增加相关(RR 3.07;95% CI 1.73-5.43;I2=0%;14项试验)。
  • 大麻素与严重不良事件风险增加相关(RR 1.81;95% CI 1.21-2.71;I2=59%;11项试验)。
  • 大麻素相关不良事件中RR较高的包括腹泻(RR 1.82;95% CI 1.30-2.54;I2=35%;10项试验)、天冬氨酸氨基转移酶血清水平升高(RR 5.69;95% CI 1.74-18.64;I2=0%;5项试验)、丙氨酸氨基转移酶升高(RR 5.67;95% CI 2.23-14.39;I2=0%;6项试验)和嗜睡(RR 2.28;95% CI 1.83-2.85;I2=8%;14项试验)。

临床怎么用

  • 临床使用医用大麻素时应监测不良事件,特别是腹泻、转氨酶升高和嗜睡。
  • 需警惕严重不良事件和因不良事件导致的治疗退出。
  • 建议开展长期安全性研究,包括探索大麻素相关药物相互作用和改进不良事件报告工具。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Cannabinoids are increasingly used for medical purposes in children. Evidence of the safety of cannabinoids in this context is sparse, creating a need for reliable information to close this knowledge gap. OBJECTIVE: To study the adverse event profile of cannabinoids used for medical purposes in children and adolescents. DATA SOURCES: For this systematic review and meta-analysis, MEDLINE, Embase, PsycINFO, and the Cochrane Library were searched for randomized clinical trials published from database inception to March 1, 2024, for subject terms and keywords focused on cannabis and children and adolescents. Search results were restricted to human studies in French or English. STUDY SELECTION: Two reviewers independently performed the title, abstract, and full-text review, data extraction, and quality assessment. Included studies enrolled at least 1 individual 18 years or younger, had a natural or pharmaceutical cannabinoid used as an intervention to manage any medical condition, and had an active comparator or placebo. DATA EXTRACTION AND SYNTHESIS: Two reviewers performed data extraction and quality assessment independently. The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline and PRISMA-S guideline were used. Data were pooled using a random-effects model. MAIN OUTCOMES AND MEASURES: The primary outcome was the incidence of withdrawals, withdrawals due to adverse events, overall adverse events, and serious adverse events in the cannabinoid and control arms. Secondary outcomes were the incidence of specific serious adverse events and adverse events based on organ system involvement. RESULTS: Of 39 175 citations, 23 RCTs with 3612 participants were included (635 [17.6%] female and 2071 [57.3%] male; data not available from 2 trials); 11 trials (47.8%) included children and adolescents only, and the other 12 trials (52.2%) included children, adolescents, and adults. Interventions included purified cannabidiol (11 [47.8%]), nabilone (4 [17.4%]), tetrahydrocannabinol (3 [13.0%]), cannabis herbal extract (3 [13.0%]), and dexanabinol (2 [8.7%]). The most common indications were epilepsy (9 [39.1%]) and chemotherapy-induced nausea and vomiting (7 [30.4%]). Compared with the control, cannabinoids were associated with an overall increased risk of adverse events (risk ratio [RR], 1.09; 95% CI, 1.02-1.16; I2 = 54%; 12 trials), withdrawals due to adverse events (RR, 3.07; 95% CI, 1.73-5.43; I2 = 0%; 14 trials), and serious adverse events (RR, 1.81; 95% CI, 1.21-2.71; I2 = 59%; 11 trials). Cannabinoid-associated adverse events with higher RRs were diarrhea (RR, 1.82; 95% CI, 1.30-2.54; I2 = 35%; 10 trials), increased serum levels of aspartate aminotransferase (RR, 5.69; 95% CI, 1.74-18.64; I2 = 0%; 5 trials) and alanine aminotransferase (RR, 5.67; 95% CI, 2.23-14.39; I2 = 0%; 6 trials), and somnolence (RR, 2.28; 95% CI, 1.83-2.85; I2 = 8%; 14 trials). CONCLUSIONS AND RELEVANCE: In this systematic review and meta-analysis, cannabinoids used for medical purposes in children and adolescents in RCTs were associated with an increased risk of adverse events. The findings suggest that long-term safety studies, including those exploring cannabinoid-related drug interactions and tools that improve adverse event reporting, are needed.

来源:JAMA Pediatr,查看原文。版权归原作者所有。

引用

  1. Chhabra M, Ben-Eltriki M, Mansell H, et al. Cannabinoids Used for Medical Purposes in Children and Adolescents: A Systematic Review and Meta-Analysis. JAMA Pediatr. 2024. PMID: 39283619. doi:10.1001/jamapediatrics.2024.3045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。